Chembio Diagnostic Systems, Inc. of Medford, NY at MEDICA 2017 in Düsseldorf -- COMPAMED Trade Fair

Chembio Diagnostic Systems, Inc.

3661 Horseblock Road, 11763 Medford, NY
United States of America

Telephone +1 631 9241135
Fax +1 631 9242065
info@chembio.com

This company is co-exhibitor of
Messe Düsseldorf North America

Hall map

MEDICA 2017 hall map (Hall 3): stand C30-16

Fairground map

MEDICA 2017 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.05  Infectious Immunology
  • 03.05.03  Equipment and systems for HIV determination units

Equipment and systems for HIV determination units

Our products

Product category: Equipment and systems for HIV determination units

DPP® HIV 1/2 Assay

CLIA-WAIVED BLOOD AND ORAL FLUID TEST

Chembio has developed a NEXT GENERATION DPP® assay using patented DPP® technology for the rapid detection of HIV 1 and HIV 2 antibodies in oral fluid and all blood matrices. The Chembio DPP® HIV 1/2 Assay is intended for use as a point-of-care test to aid in the diagnosis of infection with HIV 1 and HIV 2. This test is suitable for use in multi-test algorithms that have been established in many countries or as a standalone initial test.

More Less

Product category: Equipment and systems for HIV determination units

DPP® HIV-Syphilis Assay

Chembio Diagnostic Systems has developed the first dual HIV 1/2 and Syphilis Point-of-Care (POC) test utilizing Chembio’s patented Dual Path Platform (DPP®) technology. The Chembio DPP® HIV-Syphilis Assay is a single-use, immunochromatographic, rapid test for the detection of antibodies to Human Immunodeficiency Virus Types 1 and 2 (HIV 1/2) and Treponema pallidum (the causative agent of syphilis) in fingerstick whole blood, venous whole blood, serum, and plasma.

The Chembio DPP® HIV-Syphilis Assay is intended for use as a point-of-care test to aid in the diagnosis of infection with HIV and/or Syphilis. This test is suitable for use in multi-test algorithms designed for the statistical validation of rapid HIV test results.

A unique feature of this kit is Chembio’s new DPP®SampleTainer® bottle which contains a premeasured dilution buffer within a closed vial that also serves as a dropper for performing the assay. Smart, easy and efficient!

More Less

About us

Company details

We enable longer and healthier living through detection and monitoring of serious disease

At Chembio, our mission is to be a leader in the development, manufacture and commercialization of diagnostic solutions. We are dedicated to delivering exceptional products that provide ease of use, and rapid and accurate results at the point-of-care (POC). As a global company, we are committed to innovation and the highest quality standards.

At the core of our commitment is our patented Next Generation DPP® (Dual Path Platform) technology. Our DPP® technology is a breakthrough in POC diagnostics, offering significant advantages over lateral-flow technologies including:

  • Significantly improved sensitivity
  • Multiplexing – multiple test results via a single blood sample (e.g., HIV-Syphilis Assay)
  • Application in a number of indications
Today our DPP® technology is the basis of multiple collaborations with healthcare innovators and leaders worldwide spanning infectious diseases such as HIV, Zika, Ebola, syphilis, malaria and febrile illness, as well as potential new uses in the diagnosis of a specific form of cancer and brain injury (concussion).

OUR CORE STRENGTHS
Chembio’s core strengths are in its quality, product development, manufacturing and commercialization expertise.
In particular, Chembio’s quality standards distinguish us within the industry. We are committed to providing quality products that meet or exceed the needs of our customers. Quality is built into all steps of our process from design, manufacture, testing, release, and delivery through to customer service.
This focus on quality has shaped our product development and manufacturing processes. All of our products meet the highest standards of safety, reliability and effectiveness, and all are manufactured by Chembio at our state-of-the art production facility, which is licensed by the U.S. Food and Drug Administration (FDA) as well as the U.S. Department of Agriculture (USDA), and is certified for the global market under the International Organization for Standardization, ISO 13485, the standard for quality management systems in the medical device industry.
To effectively commercialize our products, Chembio has established a sales and marketing infrastructure led by a team of seasoned and successful professionals to expand our current markets and penetrate new markets worldwide.

In December 2016 Chembio completed the acquisition of RVR Diagnostics Sdn Bhd a Kuala Lumpur, Malaysia manufacturer of rapid diagnostic products. RVR is now a full manufacturing, supply and center of excellence facility of Chembio producing both RVR and Chembio products to serve the Asia markets.

PRODUCTS AND PARTNERSHIPS
Chembio has products on the market in over 40 countries primarily for the rapid and early detection of HIV and syphilis. Chembio markets its SURE CHECK®HIV 1/2, DPP® HIV 1/2 and HIV 1/2 STAT-PAK® Assay in the U.S. through its direct sales force and through distributors. Outside the U.S., Chembio markets its DPP® HIV 1/2, HIV 1/2 STAT-PAK®, Chagas STAT-PAK®, DPP® HIV-Syphilis, SURE CHECK® HIV 1/2 and STAT-VIEW® HIV 1/2 Assays primarily through distributors.

Equally important, Chembio has a strong development pipeline that we believe will serve as a significant growth driver in the future. Our internal development effort is currently focused on next generation diagnostics for multiplex HIV-syphilis combination testing and its fever disease portfolio including single and multiplex tests for Zika, chikungunya and dengue.

In addition, Chembio is a party to multiple collaborations, all of which seek to develop new and innovative products to address some of the world’s most serious diseases and conditions. Based on the power and versatility of our DPP® technology, we are working with our partners to develop next generation products that we hope will enable early and improved treatment of malaria, Ebola, febrile illness, dengue fever and influenza. Beyond infectious disease, we are now demonstrating the potential utility of the DPP® platform in traumatic brain injury and in a specific form of cancer.

Together, we believe our DPP® technology, existing products, internal development expertise and global partnerships create a strong platform for innovation to improve today’s testing and treatment paradigms for the betterment of healthcare everywhere.

CHEMBIO’S STRATEGY AND FUTURE
Chembio’s mission, products and partnerships form the cornerstone of the company’s three-pronged strategic plan:

  • Expand our product pipeline with high-value diagnostics for which there is significant need
  • Establish an effective and wide-reaching commercialization organization to deliver our products to patients worldwide
  • Leverage our technology and our global partnerships to build an infrastructure that will sustain future growth and strengthen the Chembio brand
With our DPP® platform, our exceptional scientific and commercialization personnel, and world class partners, Chembio is positioned to be a true leader in diagnostic solutions and improve healthcare around the world through early, rapid and innovative testing.

More Less